- Conditions
- Ovarian Cancer, Ovarian Carcinoma, Endometrial Cancer, Uterine Cancer, Cervical Cancer, Vulvar Cancer, Gynecologic Cancer, Vaginal Cancer
- Interventions
- Belzutifan
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 197
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Endometrial Cancer
- Interventions
- medroxyprogesterone
- Drug
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- Female only
- Enrollment
- 360 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 30
- States / cities
- Tucson, Arizona • Los Gatos, California • Orange, California + 26 more
- Conditions
- Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Stage II Fallopian Tube Cancer AJCC v8, Stage II Ovarian Cancer AJCC v8, Stage II Primary Peritoneal Cancer AJCC v8, Stage III Fallopian Tube Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8
- Interventions
- Behavioral Intervention, Best Practice, Biospecimen Collection, Electronic Health Record Review, Exercise Intervention, Medical Device Usage and Evaluation, Questionnaire Administration, Supportive Care
- Behavioral · Other · Procedure
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Mixed Adenocarcinoma, Endometrial Mucinous Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Squamous Cell Carcinoma, Endometrial Transitional Cell Carcinoma, Endometrial Undifferentiated Carcinoma, Recurrent Uterine Corpus Carcinoma
- Interventions
- Brivanib Alaninate, Laboratory Biomarker Analysis
- Drug · Other
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 35
- States / cities
- Aurora, Colorado • New Britain, Connecticut • Chicago, Illinois + 19 more
- Conditions
- Complex Endometrial Hyperplasia With Atypia, Stage IA Uterine Corpus Cancer, Stage IB Uterine Corpus Cancer, Stage II Uterine Corpus Cancer
- Interventions
- Weight Loss Specialist, Quality-of-Life Assessment, Medical Chart Review
- Behavioral · Other
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 127 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Endometrial Cancer
- Interventions
- conjugated estrogens
- Drug
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- Female only
- Enrollment
- 2,108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1997
- U.S. locations
- 149
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 99 more
- Conditions
- Endometrial Adenoacanthoma, Endometrial Adenocarcinoma, Endometrial Adenosquamous Cell Carcinoma, Endometrial Clear Cell Carcinoma, Endometrial Papillary Serous Carcinoma, Recurrent Endometrial Carcinoma
- Interventions
- thalidomide, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Endometrial Cancer, Endometrial Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma
- Interventions
- Mirvetuximab Soravtansine, Bevacizumab
- Drug
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Solid Tumors and Advanced Endometrial Cancer, Endometrial Cancer, Second-line Treatment, VEGF
- Interventions
- TKI258
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 21
- States / cities
- Mobile, Alabama • Fullerton, California • Los Angeles, California + 15 more
- Conditions
- Renal Cell Cancer, Castrate Resistant Prostate Cancer, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer (CRC), Endometrial Cancer, Ovarian Cancer
- Interventions
- TT-10, TT-4
- Drug
- Lead sponsor
- Portage Biotech
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Louisville, Kentucky • Houston, Texas
- Conditions
- Endometrial Cancer Recurrent
- Interventions
- Dordaviprone (ONC201)
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 3
- States / cities
- New Brunswick, New Jersey • Chapel Hill, North Carolina • Philadelphia, Pennsylvania
- Conditions
- Cervical Cancer, Endometrial Cancer
- Interventions
- cisplatin, intensity-modulated radiation therapy
- Drug · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2016
- U.S. locations
- 151
- States / cities
- Auburn, California • Cameron Park, California • Carmichael, California + 103 more
- Conditions
- Breast Cancer, Endometrial Cancer
- Interventions
- medroxyprogesterone, tamoxifen citrate, adjuvant therapy
- Drug · Procedure
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 313 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2009
- U.S. locations
- 122
- States / cities
- Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 84 more
- Conditions
- Ovarian Neoplasms, Uterine Neoplasms
- Interventions
- Topotecan and Taxotere
- Drug
- Lead sponsor
- Montefiore Medical Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Gynecologic Cancer, Carcinoma, Uterine Cancer, Endometrial Cancer
- Interventions
- Cabo + Dostarlimab
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Endometrial Cancer
- Interventions
- BEZ235
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 16
- States / cities
- Phoenix, Arizona • Fayetteville, Arkansas • Duarte, California + 13 more
- Conditions
- Cancer
- Interventions
- therapeutic allogeneic lymphocytes
- Biological
- Lead sponsor
- University of Medicine and Dentistry of New Jersey
- Other
- Eligibility
- Not listed
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2011
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey
- Conditions
- Endometrial Cancer
- Interventions
- Letrozole, RAD001 (Everolimus)
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2028
- U.S. locations
- 2
- States / cities
- Morristown, New Jersey • Houston, Texas
- Conditions
- Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer, Sarcoma
- Interventions
- paclitaxel, pegylated liposomal doxorubicin hydrochloride
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- Up to 120 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1997
- U.S. locations
- 5
- States / cities
- New York, New York • The Bronx, New York • Valhalla, New York
- Conditions
- Gynecologic Cancer, Colorectal Cancer, Pancreatic Cancer, Non-small Cell Lung Cancer, Cholangiocarcinoma, Ovarian Cancer, Endometrial Cancer, Ovarian Carcinoma, Ovary Neoplasm, Squamous Cell Lung Cancer, Adenocarcinoma of Lung, Adenosquamous Cell Lung Cancer
- Interventions
- Neoantigen specific TCR-T cell drug product, Aldesleukin (IL-2)
- Biological
- Lead sponsor
- Alaunos Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Endometrial Cancer, Ovarian Cancer
- Interventions
- quality-of-life assessment
- Procedure
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- Female only
- Enrollment
- 311 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 43
- States / cities
- Birmingham, Alabama • Los Angeles, California • Los Gatos, California + 36 more
- Conditions
- Recurrent Uterine Corpus Carcinoma
- Interventions
- Gefitinib, Laboratory Biomarker Analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2013
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Endometrial Serous Adenocarcinoma, Stage I Uterine Corpus Cancer, Stage II Uterine Corpus Cancer, Stage III Uterine Corpus Cancer, Stage IV Uterine Corpus Cancer
- Interventions
- Diagnostic Laboratory Biomarker Analysis, Immunohistochemistry Staining Method, Medical Chart Review, Microarray Analysis, Study of Socioeconomic and Demographic Variables, Western Blotting
- Other · Genetic
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- Female only
- Enrollment
- 360 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2018
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Stage I Endometrial Carcinoma, Stage II Endometrial Carcinoma, Stage III Endometrial Carcinoma, Stage IV Endometrial Carcinoma
- Interventions
- lymph node mapping, sentinel lymph node biopsy, isosulfan blue, indocyanine green solution, therapeutic conventional surgery, lymphadenectomy
- Procedure · Drug
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- Female only
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio